TAKEDA STILL RANKS TOP IN JAPAN'S FY'07 PRESCRIPTION DRUG MARKET

Mon. July 28, 2008; Posted: 12:35 AM

TOKYO, Jul 28, 2008 (AsiaPulse via COMTEX) -- MPHMF | Quote | Chart | News | PowerRating -- Japan's Mitsubishi Tanabe Pharma Co. (TSE:4508) emerged as the fourth top firm in prescription drugs in fiscal 2007, pushing Pfizer Japan Inc. and Chugai Pharmaceutical Co. (TSE:4519) down to the fifth and sixth spots.

Mitsubishi Tanabe, which was created in October 2007 through a merger of Mitsubishi Pharma Corp. and Tanabe Seiyaku Co., captured 4.9 per cent of the market.

But this was 0.2 point less than the combined market share of the pre-merger entities in fiscal 2006 as the market outgrew the merged firm.

Ranking of the top three drugmakers remained unchanged from a year earlier, with Takeda Pharmaceutical Co. (TSE:4502) leading with 8 per cent.

Astellas Pharma Inc. (TSE:4503) and Daiichi Sankyo Co. (TSE:4568) trailed at 7.3 per cent and 6.3 per cent respectively.

The domestic market for prescription drugs grew 5.5 per cent to 8.13 trillion yen (US$75.45 billion) in fiscal 2007.

The fiscal 2006 revision of government-mandated medicine prices caused the market to shrink 0.5 per cent that year, but the absence of such price cuts helped the market's value top 8 trillion yen for the first time in fiscal 2007.

Takeda had brisk sales for the Actos diabetes drug and the Candesartan high blood pressure treatment, with its market share remaining flat.

Astellas lifted its market share 0.1 point.

Daiichi Sankyo's market share fell by 0.2 points, although sales at its domestic drug operations increased.

(Nikkei)

For full details for MPHMF click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.